MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Antonio Uccelli; Alice Laroni; Lou Brundin; Michel Clanet; Oscar Fernandez; Seyed Massood Nabavi; Paolo A Muraro; Roberto S Oliveri; Ernst W Radue; Johann Sellner; Per Soelberg Sorensen; Maria Pia Sormani; Jens Thomas Wuerfel; Mario A Battaglia; Mark S Freedman; MESEMS study group

doi:10.1186/s13063-019-3346-z

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Oscar Fernandez, Seyed Massood Nabavi, Paolo A Muraro, Roberto S Oliveri, Ernst W Radue, Johann Sellner (Co-author), Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mario A Battaglia, Mark S Freedman, MESEMS study group

Research output: Contribution to journal › Original Article › peer-review

58 Citations (Web of Science)

Original language	English
Pages (from-to)	263
Journal	Trials
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s13063-019-3346-z
Publication status	Published - 2019

Keywords

EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
NEUROLOGICAL DISEASES
TRANSPLANTATION

Access to Document

10.1186/s13063-019-3346-z

Cite this

Uccelli, A., Laroni, A., Brundin, L., Clanet, M., Fernandez, O., Nabavi, S. M., Muraro, P. A., Oliveri, R. S., Radue, E. W., Sellner, J., Soelberg Sorensen, P., Sormani, M. P., Wuerfel, J. T., Battaglia, M. A., Freedman, M. S., & MESEMS study group (2019). MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials, 20(1), 263. https://doi.org/10.1186/s13063-019-3346-z

@article{89befcb172494893a519074f57ad9542,

title = "MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.",

keywords = "EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, NEUROLOGICAL DISEASES, TRANSPLANTATION",

author = "Antonio Uccelli and Alice Laroni and Lou Brundin and Michel Clanet and Oscar Fernandez and Nabavi, {Seyed Massood} and Muraro, {Paolo A} and Oliveri, {Roberto S} and Radue, {Ernst W} and Johann Sellner and {Soelberg Sorensen}, Per and Sormani, {Maria Pia} and Wuerfel, {Jens Thomas} and Battaglia, {Mario A} and Freedman, {Mark S} and {MESEMS study group} and Eva Rohde and Mario Gimona and Dirk Strunk",

note = "Sellner: Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, Salzburg, Austria; study gr member; Rohde: (Department of Blood Group Serology and Transfusion Medicine, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria; Gimona: GMP Unit, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria; Strunk: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University, Salzburg, Austria",

year = "2019",

doi = "10.1186/s13063-019-3346-z",

language = "English",

volume = "20",

pages = "263",

journal = "Trials",

issn = "1745-6215",

publisher = "Springer Nature",

number = "1",

}

Uccelli, A, Laroni, A, Brundin, L, Clanet, M, Fernandez, O, Nabavi, SM, Muraro, PA, Oliveri, RS, Radue, EW, Sellner, J, Soelberg Sorensen, P, Sormani, MP, Wuerfel, JT, Battaglia, MA, Freedman, MS & MESEMS study group 2019, 'MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.', Trials, vol. 20, no. 1, pp. 263. https://doi.org/10.1186/s13063-019-3346-z

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. / Uccelli, Antonio; Laroni, Alice; Brundin, Lou et al.
In: Trials, Vol. 20, No. 1, 2019, p. 263.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

AU - Uccelli, Antonio

AU - Laroni, Alice

AU - Brundin, Lou

AU - Clanet, Michel

AU - Fernandez, Oscar

AU - Nabavi, Seyed Massood

AU - Muraro, Paolo A

AU - Oliveri, Roberto S

AU - Radue, Ernst W

AU - Sellner, Johann

AU - Soelberg Sorensen, Per

AU - Sormani, Maria Pia

AU - Wuerfel, Jens Thomas

AU - Battaglia, Mario A

AU - Freedman, Mark S

AU - MESEMS study group

A2 - Rohde, Eva

A2 - Gimona, Mario

A2 - Strunk, Dirk

N1 - Sellner: Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, Salzburg, Austria; study gr member; Rohde: (Department of Blood Group Serology and Transfusion Medicine, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria; Gimona: GMP Unit, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria; Strunk: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University, Salzburg, Austria

PY - 2019

Y1 - 2019

KW - EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

KW - NEUROLOGICAL DISEASES

KW - TRANSPLANTATION

U2 - 10.1186/s13063-019-3346-z

DO - 10.1186/s13063-019-3346-z

M3 - Original Article

C2 - 31072380

SN - 1745-6215

VL - 20

SP - 263

JO - Trials

JF - Trials

IS - 1

ER -